UA26953C2 - Речовиhа для подолаhhя мультилікарської стійкості - Google Patents
Речовиhа для подолаhhя мультилікарської стійкостіInfo
- Publication number
- UA26953C2 UA26953C2 UA93002239A UA93002239A UA26953C2 UA 26953 C2 UA26953 C2 UA 26953C2 UA 93002239 A UA93002239 A UA 93002239A UA 93002239 A UA93002239 A UA 93002239A UA 26953 C2 UA26953 C2 UA 26953C2
- Authority
- UA
- Ukraine
- Prior art keywords
- resistance
- multicarking
- overcoming
- substances
- control
- Prior art date
Links
- 239000000126 substance Substances 0.000 title 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 abstract 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 229960004574 azelastine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229950006000 flezelastine Drugs 0.000 abstract 1
- 230000036457 multidrug resistance Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4233113 | 1992-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA26953C2 true UA26953C2 (uk) | 1999-12-29 |
Family
ID=6469448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA93002239A UA26953C2 (uk) | 1992-10-02 | 1993-09-30 | Речовиhа для подолаhhя мультилікарської стійкості |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5556856A (enExample) |
| EP (1) | EP0590551B1 (enExample) |
| JP (1) | JP3623975B2 (enExample) |
| CN (1) | CN1088435A (enExample) |
| AT (1) | ATE144708T1 (enExample) |
| AU (1) | AU666773B2 (enExample) |
| CA (1) | CA2107548A1 (enExample) |
| CZ (1) | CZ199593A3 (enExample) |
| DE (1) | DE59304351D1 (enExample) |
| DK (1) | DK0590551T3 (enExample) |
| ES (1) | ES2096168T3 (enExample) |
| GR (1) | GR3022070T3 (enExample) |
| HU (1) | HUT65353A (enExample) |
| MX (1) | MX9306120A (enExample) |
| RU (1) | RU2106143C1 (enExample) |
| SK (1) | SK104493A3 (enExample) |
| UA (1) | UA26953C2 (enExample) |
| ZA (1) | ZA937315B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162616A (en) * | 1997-04-16 | 2000-12-19 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2003041128A2 (en) * | 2001-11-07 | 2003-05-15 | Pharmacia Corporation | Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| US20080039444A1 (en) * | 2006-04-20 | 2008-02-14 | Glaxo Group Limited | Compounds |
| WO2007144639A1 (en) * | 2006-06-15 | 2007-12-21 | Kudos Pharmaceuticals Limited | 2 -oxybenzamide derivatives as parp inhibitors |
| US20090181951A1 (en) * | 2006-06-15 | 2009-07-16 | Kudos Pharmaceuticals Limited | Parp inhibitors |
| US20090281086A1 (en) * | 2006-06-15 | 2009-11-12 | Kudos Pharmaceuticals Limited | 2 -oxyheteroarylamide derivatives as parp inhibitors |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US20100184770A1 (en) * | 2006-12-20 | 2010-07-22 | Glaxo Group Limited | Compounds |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| MX2010002749A (es) | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
| ATE525370T1 (de) * | 2007-10-11 | 2011-10-15 | Glaxo Group Ltd | Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten |
| CA2702429A1 (en) | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| CA2737400C (en) * | 2008-10-07 | 2016-11-22 | Astrazeneca Uk Limited | Pharmaceutical formulation 514 |
| US20110015393A1 (en) * | 2009-07-15 | 2011-01-20 | Astrazeneca Ab | Phthalazinone compound |
| EP2968323A4 (en) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2031813T3 (es) * | 1985-11-11 | 1993-01-01 | Asta Pharma Ag | Procedimiento para la preparacion de derivados de 4-bencil-1-(2h)-ftalazinona. |
| JPH0667844B2 (ja) * | 1987-03-06 | 1994-08-31 | エーザイ株式会社 | 虚血性心疾患の治療・予防剤 |
| US5110814A (en) * | 1989-01-11 | 1992-05-05 | Asta Pharma Ag | Azelastine and its salts used to combat psoriasis |
-
1993
- 1993-09-24 CZ CZ931995A patent/CZ199593A3/cs unknown
- 1993-09-25 AT AT93115512T patent/ATE144708T1/de not_active IP Right Cessation
- 1993-09-25 EP EP93115512A patent/EP0590551B1/de not_active Expired - Lifetime
- 1993-09-25 DK DK93115512.1T patent/DK0590551T3/da active
- 1993-09-25 DE DE59304351T patent/DE59304351D1/de not_active Expired - Lifetime
- 1993-09-25 ES ES93115512T patent/ES2096168T3/es not_active Expired - Lifetime
- 1993-09-29 CN CN93118175A patent/CN1088435A/zh active Pending
- 1993-09-30 UA UA93002239A patent/UA26953C2/uk unknown
- 1993-09-30 SK SK1044-93A patent/SK104493A3/sk unknown
- 1993-10-01 HU HU9302784A patent/HUT65353A/hu unknown
- 1993-10-01 MX MX9306120A patent/MX9306120A/es unknown
- 1993-10-01 RU RU93056139A patent/RU2106143C1/ru active
- 1993-10-01 ZA ZA937315A patent/ZA937315B/xx unknown
- 1993-10-01 JP JP24683493A patent/JP3623975B2/ja not_active Expired - Fee Related
- 1993-10-01 AU AU48769/93A patent/AU666773B2/en not_active Ceased
- 1993-10-01 CA CA002107548A patent/CA2107548A1/en not_active Abandoned
-
1995
- 1995-04-04 US US08/416,467 patent/US5556856A/en not_active Expired - Fee Related
-
1996
- 1996-12-18 GR GR960403515T patent/GR3022070T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU666773B2 (en) | 1996-02-22 |
| RU2106143C1 (ru) | 1998-03-10 |
| US5556856A (en) | 1996-09-17 |
| GR3022070T3 (en) | 1997-03-31 |
| ZA937315B (en) | 1994-04-22 |
| EP0590551A3 (enExample) | 1994-08-31 |
| DK0590551T3 (da) | 1997-04-21 |
| JPH06312928A (ja) | 1994-11-08 |
| SK104493A3 (en) | 1994-08-10 |
| CN1088435A (zh) | 1994-06-29 |
| DE59304351D1 (de) | 1996-12-05 |
| CZ199593A3 (en) | 1994-04-13 |
| CA2107548A1 (en) | 1994-04-03 |
| ES2096168T3 (es) | 1997-03-01 |
| EP0590551B1 (de) | 1996-10-30 |
| AU4876993A (en) | 1994-04-14 |
| JP3623975B2 (ja) | 2005-02-23 |
| HU9302784D0 (en) | 1993-12-28 |
| EP0590551A2 (de) | 1994-04-06 |
| MX9306120A (es) | 1994-04-29 |
| HUT65353A (en) | 1994-05-02 |
| ATE144708T1 (de) | 1996-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA26953C2 (uk) | Речовиhа для подолаhhя мультилікарської стійкості | |
| DE69215434D1 (de) | 1,3,5-Triazinderivate, ihre Herstellung und ihre Verwendung als Lichtschutzmittel | |
| FR2696176B1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. | |
| NO915113D0 (no) | Substituerte imidazoler | |
| DE3789320D1 (de) | Verabreichungsinstrument zum Einführen von festen Medikamenten. | |
| DE59203666D1 (de) | Medizinische Zange. | |
| DE69333513D1 (de) | Rohrförmige, medizinische endoprothese | |
| DE68911389D1 (de) | Medizinische Vorrichtungen. | |
| FI881177A0 (fi) | Anordning foer positionering av en patient i en medicinsk panoramaroentgenfotograferingsanordning. | |
| FR2710915B1 (fr) | Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique. | |
| DE69029231D1 (de) | Indolderivate, ihre herstellung und diese enthaltendes arzneimittel zum verhindern und behandeln von nephritis | |
| DE69222380D1 (de) | Lateraler, bipolarer Transistor mit isolierter Steuerelektrode und entsprechende Mehrfachanordnung | |
| IT1237129B (it) | Composti piperidin-triazinici atti all'impiego come stabilizzanti per materiali organici. | |
| DE69201302D1 (de) | Therapeutische zusammenstellungen auf der basis von 1,2-dithiole-3-thionderivaten. | |
| NO171851C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktivt 6-cyano-4-(1,2-dihydro-2-okso-pyrid-1-yl)-2,2-dimetylkromen | |
| DE69324718D1 (de) | Thermisch abhängige, selbständernde Spannungsquelle | |
| FR2696177B1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. | |
| DE69806465D1 (de) | Eine heteroethynylen-brücke enthaltende bi-aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammensetzungen | |
| IT1246779B (it) | Composti piperidinici atti all'impiego come stabilizzanti per materiali organici. | |
| DE68913866D1 (de) | Ablaufschacht, Destillationsbodenanordnung und Destillationskolonne. | |
| DE69208681D1 (de) | Verwendungen von 1,1,1,3,3,3-hexafluoropropan | |
| NO923266D0 (no) | Heksahydrobenzo(f)quinolinoner | |
| ES2072869T3 (es) | Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo. | |
| NO170282C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,4-diazepinderivater | |
| FI941077A7 (fi) | Reseptorijohdannaiset, joissa on sitoutumispaikkoja ihmisen nuhaviruks ille |